ResMed Q4 FY26 GAAP diluted EPS rises 2% to $2.64; revenue increases 9% to $1.46 billion
PUBT · 3d ago
Share
Listen to the news
- ResMed Q4 FY2026 revenue rose 9% to USD 1.46 billion from June 30, 2025 period; GAAP diluted EPS increased 2% to USD 2.64.
- GAAP operating income slipped 1% to USD 448.71 million; GAAP gross margin narrowed 2 percentage points to 58.8%.
- Non-GAAP diluted EPS climbed 16% to USD 2.95; non-GAAP gross margin widened 0.9 percentage points to 62.3%.
- FY2026 revenue increased 10% to USD 5.65 billion; GAAP diluted EPS rose 10% to USD 10.43.
- Guided to more than USD 1.85 billion of shareholder returns in FY2027; raised quarterly dividend 10% to USD 0.66.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805536) on August 06, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending